InvestLog
ANEB Anebulo Pharmaceuticals, Inc. logo

ANEB Anebulo Pharmaceuticals, Inc.

Healthcare
$0.46+0.00%ClosedMarket Cap: $18.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.38

P/S

0.00

EV/EBITDA

-1.17

DCF Value

$0.34

FCF Yield

-31.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-74.6%

ROA

-84.7%

ROIC

-102.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$0.00$-2.0M$—
Q1 null$0.00$-2.2M$—
Q4 null$0.00$-2.1M$—
FY null$0.00$-8.5M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell
Maxim GroupHold
2025-07-23

Trading Activity

Insider Trades

View All
SHAH BIMAL R.director
SellMon Apr 07
SHAH BIMAL R.director
SellMon Apr 07
Lin Kennethdirector
SellMon Apr 07
Lin Kennethdirector
SellMon Apr 07
Lawler Joseph F.director, 10 percent owner:
SellMon Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

-1.94

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Peers

CLNN logoCLNNCOYA logoCOYAESLA logoESLAIMMX logoIMMXMGNX logoMGNXOKYO logoOKYOPLRX logoPLRXTLSA logoTLSAWHWK logoWHWKZNTL logoZNTL